Albert Samadi, MD
Urology · Valencia, CANPI 1619952637
Payments from drug & device makers
Across 53 payments — averaging $98.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Procept Biorobotics Corporation$1K
- Neotract Inc.$1K
- EDAP Technomed Inc$312
- Dornier Medtech America, Inc$190
- Teleflex LLC$175
- plus $686 from 12 others
What the payments were for
- Travel & lodging$3,07959%
- Food & beverage$2,15141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $1,335 |
| Procept Biorobotics Corporation | 4 | $1,278 |
| Neotract Inc. | 11 | $1,254 |
| EDAP Technomed Inc | 3 | $312 |
| Dornier Medtech America, Inc | 4 | $190 |
| Teleflex LLC | 2 | $175 |
| Olympus America Inc. | 4 | $161 |
| Astellas Pharma US Inc | 1 | $125 |
| Heron Therapeutics, Inc. | 1 | $107 |
| Coloplast | 5 | $74 |
| Endo Pharmaceuticals Inc. | 2 | $45 |
| Bluewind Medical | 2 | $44 |
| Myriad Genetic Laboratories, Inc. | 2 | $36 |
| Calyxo, Inc. | 1 | $32 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $13 |
| Acell, Inc. | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lumenis Pulse 120H$1,286
- AquaBeam Robotic System$1,231
- UroLift$1,098
- XTANDI$125
- iTIND System$110
- Zynrelef$107
- Consumables & Accessories$104
How this compares
$5,230 in reported general payments places this provider in the 60th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 30 | $35,519 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 135 | $3,561 |
| Tamsulosin Hcl | 196 | $2,715 |
| Finasteride | 150 | $2,361 |
| Methenamine Hippurate | 16 | $2,086 |
| Tadalafil | 16 | $1,143 |
| Bicalutamide | 27 | $1,095 |
| Doxazosin Mesylate | 56 | $743 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $441 |
| Levofloxacin | 101 | $286 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $214 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 37 | $133 |
| Ciprofloxacin Hcl | 29 | $98 |
| Terazosin Hcl | 11 | $87 |
| Sildenafil Citrate | 13 | $76 |
Paid to pharmacies, not to this prescriber.
Other urology in Valencia
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.